| Scorecard |
|---|
|
3 / 5 Stars
|
|
Lipper
5
5
3
4
1
|
|
Zacks Investment Research
5
(Strong Sell)
|
|
Standard & Poor's
4 / 5 Stars
|
|
TheStreet.com
D+
(Sell)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 1.5 | 1.5 |
| Stocks | 38.14 | 38.14 |
| Bonds | 0.08 | 0.08 |
| Other | 0.58 | 0.58 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 59.7 | 59.7 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Roche Holding AG | RHHVF | 23.65 | 2.34 |
| Morgan Stanley | MS | 14.8 | 2.25 |
| Citigroup Inc | C | 15.98 | 2.24 |
| Pfizer Inc | PFE | 16.19 | 2.17 |
| Sanofi | SAN | --- | 2.13 |
| Credit Suisse Group | CSGN | --- | 2.13 |
| Samsung Electronics Co Ltd | SSNLF | 0.0 | 2.12 |
| Cisco Systems Inc | CSCO | 4.58 | 2.0 |
| Microsoft Corporation | MSFT | 23.36 | 1.97 |
| GlaxoSmithKline PLC | GLAXF | 20.09 | 1.96 |
